Cart
sales@molnova.com
Tenofovir amibufenamide
CAS No. 1571076-26-0
Tenofovir amibufenamide( —— )
Catalog No. M35088 CAS No. 1571076-26-0
Tenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 550 | In Stock |
|
| 10MG | 825 | In Stock |
|
| 25MG | 1321 | In Stock |
|
| 50MG | 1795 | In Stock |
|
| 100MG | 2465 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTenofovir amibufenamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionTenofovir amibufenamide (HS-10234) is a Tenofovir prodrug, an antiviral compound with oral activity. Tenofovir amibufenamide inhibits hepatitis B virus (HBV) and can be used in chronic hepatitis B (CHB) studies.
-
DescriptionTenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1571076-26-0
-
Formula Weight490.49
-
Molecular FormulaC22H31N6O5P
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (407.76 mM; Ultrasonic )
-
SMILESC([C@H](OCP(OC1=CC=CC=C1)(NC(C(OC(C)C)=O)(C)C)=O)C)N2C=3C(N=C2)=C(N)N=CN3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149.?
molnova catalog
related products
-
Isothiafludine
Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM.
-
BCM-599
BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
-
?-Thujaplicinol
?-Thujaplicinol, a hydroxylated thujaplicinone isolated from western red cedar heartwood, has antiviral activity, inhibits hepatitis B virus replication by blocking viral ribonuclease H activity, and can be used in the study of viral infections.
